Kidney cancer is a disease characterized by the uncontrolled proliferation of cells within the renal tissue. The most common subtype, clear cell renal cell carcinoma (ccRCC), accounts for the majority of cases and is frequently associated with the inactivation of the tumor suppressor gene von Hippel-Lindau (VHL). This genetic alteration disrupts cancer metabolism and mitochondrial function, leading to tumor progression and metastasis. Research on the role of mitochondrial complex I in ccRCC cells provides crucial insights into how these metabolic disruptions promote metastasis; however, generalizing these laboratory findings to real patient populations and validating the effectiveness of clinical treatment strategies remain significant challenges. To overcome these limitations, personalized treatment approaches and next-generation therapies are being proposed as potential solutions.
Smith and colleagues conducted an in-depth investigation into the role of mitochondrial complex I in metastasis within ccRCC cells. In their study, they assessed the metabolic profile of ccRCC cells by administering 13C-labeled nutrient infusions during surgical interventions in more than 80 kidney cancer patients. The research revealed that [U-13C] glucose labeling varied across tumor subtypes and that renal tissue alone could not account for the metabolic reprogramming of the tumor. Additionally, experiments conducted in vivo and in ex vivo organotypic cultures demonstrated that labeling within the tricarboxylic acid (TCA) cycle was suppressed in ccRCC cells but significantly increased in metastatic tumors. These findings highlight the critical role of mitochondrial complex I in the metastatic process and offer valuable insights into how metastatic potential is triggered.
The study findings indicate that in mouse model experiments, enhancing respiration or NADH recycling in kidney cancer cells promotes metastasis, while inhibition of complex I in the electron transport chain significantly reduces metastasis. Furthermore, gene expression analyses conducted on human ccRCC samples revealed that higher expression of genes associated with oxidative phosphorylation (OxPhos) in primary tumors, particularly in advanced-stage and high-grade tumors, correlates with poor patient survival. These results underscore the impact of mitochondrial dysfunction on metabolic characteristics during metastasis and support the critical role of complex I in the metastatic process.
In conclusion, this research presents significant innovations for kidney cancer treatment. Targeting mitochondrial complex I could enable the development of new therapeutic strategies aimed at preventing metastasis. Future studies should focus on applying these findings to broader patient populations, validating the efficacy of treatment approaches in clinical settings, and creating innovative strategies to prevent disease progression, all of which could lead to major advances in kidney cancer therapy. Additionally, using mitochondrial function and gene expression profiles as prognostic biomarkers is expected to support personalized medicine applications, ultimately leading to improved patient outcomes and long-term survival rates.
Author: Ayşe Akçam
Editor: Elif Duymaz
Reference: Bezwada, D., Perelli, L., Lesner, N. P., Cai, L., Brooks, B., Wu, Z., Vu, H. S., Sondhi, V., Cassidy, D. L., Kasitinon, S., Kelekar, S., Cai, F., Aurora, A. B., Patrick, M., Leach, A., Ghandour, R., Zhang, Y., Do, D., McDaniel, P., . . . DeBerardinis, R. J. (2024). Mitochondrial complex I promotes kidney cancer metastasis. Nature. https://doi.org/10.1038/s41586-024-07812-3
-Bioinfocodes Scientific News Service-
News articles prepared by our team members, reviewing and compiling scientific research published in journals with an impact factor greater than 20 (click here for the list).